June 4th, 2025
We participated in the 2025 Annual Meeting of the American Society of Clinical Oncology (ASCO)
We, Stella Pharma, participated in the 2025 Annual Meeting of the American Soci……
Information
May 23rd, 2025
Statistically Significant Difference in Results for Primary Endpoint of Clinical Trial for Recurrent High-Grade Meningioma – Presentation at the 2025 Annual Meeting of the American Society of Clinical Oncology (ASCO)
Stella Pharma is pleased to announce the results of the Phase II investigator-i……
April 15th, 2025
Phase I/II Clinical Trial in Japan for Thoracic Malignant Solid Tumors has started
Stella Pharma announces that it has started the first patient trial for the do……
April 9th, 2025
Presentation on the Clinical Trial for Recurrent High-Grade Meningioma at the 2025 Annual Meeting of the American Society of Clinical Oncology (ASCO)
At the 2025 Annual Meeting of the American Society of Clinical Oncology (ASCO),……
We are proud to announce that we will exhibit at the Osaka Healthcare Pavilion ……
We are pleased to announce that we have successfully completed the first shipme……
December 25th, 2024
Stella Pharma Concludes MOU on Boron Neutron Capture Therapy System with Fujita Health University, Atransen Pharma, SHI, and Fujita
Stella Pharma Corporation has concluded a Memorandum of Understanding (MOU) to ……
December 6th, 2024
Paper published: Poly(vinyl alcohol) Potentiating an Inert D-Amino Acid-Based Drug for Boron Neutron Capture Therapy
The paper titled “Poly(vinyl alcohol) potentiating an inert D-amino acid-based ……
November 20th, 2024
Paper published: Research on Combination of Proton Beam Therapy and Boron Nuclear Capture Reaction
The Paper titled “Increased cell killing effect in neutron capture enhanced pro……
September 6th, 2024
Conclusion of an Agreement with the National Cancer Center, Sumitomo Heavy Industries, Ltd. and CICS, Inc. for Clinical Trial of BNCT
Stella Pharma announces that it has signed an agreement with the National Cance……
August 30th, 2024
Paper published: Research on Combination Therapy of BNCT and Immune Checkpoint Inhibitors
The Paper “Overcoming immunotherapy resistance and inducing abscopal effects wi……
August 30th, 2024
Application for Orphan Drug Designation: Borofalan (10B) for Recurrent Malignant Glioma and Recurrent Meningioma
Stella Pharma announces that it has applied to the Japanese Ministry of Health,……
